Clinical Trial Update: Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults [Phase 1]

View source ↗

Summary

Phase 1 trial update of the Plasmodium vivax Pvs230D1-EPA/Matrix-M malaria vaccine in healthy malaria-naive adults. The study evaluated safety, immunogenicity, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Pvs230D1-EPA/Matrix-M

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Malaria | Phase 1 | Status: COMPLETED